Immunohistochemical detection of HIF-1α and CAIX in advanced head-and-neck cancer: Prognostic role and correlation with tumor markers and tumor oxygenation (Strahlentherapie und Onkologie (2008) 184 (393-399) DOI: 10.1007/s00066-008-1813-7);Immunohistochemical detection of HIF-1α and CAIX in advanced head-and-neck cancer: Prognostic role and correlation with tumor markers and tumor oxygenation parameters

Strahlentherapie und Onkologie

Volumn 184, Issue 8, 2008, Pages 393-399

  Kappler, Matthias ^a   Taubert, Helge ^a   Holzhausen, Hans Jürgen ^a   Reddemann, Rolf ^a   Rot, Swetlana ^a   Becker, Axel ^a   Kuhnt, Thomas ^a   Dellas, Kathrin ^a   Dunst, Jürgen ^b   Vordermark, Dirk ^a,c   Hänsgen, Gabriele ^a   Bache, Matthias ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CAIX; Head and neck cancer; HIF 1 ; Prognosis

Indexed keywords

CARBONATE DEHYDRATASE IX; CISPLATIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MITOMYCIN C; OSTEOPONTIN; PACLITAXEL; PROTEIN P53; SURVIVIN; TUMOR MARKER; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; HIF1A PROTEIN, HUMAN; TUMOR ANTIGEN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PARAMETER; PH; PROGNOSIS; PROTEIN EXPRESSION; TISSUE OXYGENATION; TISSUE SECTION; TREATMENT OUTCOME; TUMOR HYPOXIA; TUMOR OXYGENATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CELL HYPOXIA; HEAD AND NECK TUMOR; HEMOGLOBIN DETERMINATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; RADIATION DOSE FRACTIONATION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBONIC ANHYDRASES; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEMOGLOBINOMETRY; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56149101369     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-9813-1     Document Type: Erratum

References (42)

1. Axelson H, Fredlund E, Ovenberger M, et al. Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554-63.
2. Bache M, Holzapfel D, Kappler M, et al. Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007;104:139-44.
3. Bache M, Kappler M, Said HM, et al. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008;15:322-38.
4. Bache M, Reddemann R, Said HM, et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 2006;66:1481-7.
5. Becker A, Stadler P, Krause U, et al. [No association between p53 overexpression and polarographically measured tumor oxygenation in patients with head and neck carcinomas.] Strah lenther Onkol 2000;176:475-80.
6. Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66.
7. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
8. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
9. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008;68:152-61.
10. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
11. Gagel B, DiMartino E, Schramm O, et al. Contrast-enhanced color duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumor oxygenation? Strahlenther Onkol 2006;182:604-9.
12. Hoogsteen IJ, Marres HA, Bussink J, et al. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 2007;29:591-604.
13. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604.
14. Janssen HL, Haustermans KM, Sprong D, et al. HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002;54:1537-1549.
15. Kaluz S, Kaluzova M, Chrastina A, et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 2002;62:4469-77.
16. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325-35.
17. Kimura H, Weisz A, Kurashima Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-97.
18. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35.
19. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
20. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.
21. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
22. Mayer A, Hockel M, Vaupel P. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Strahlenther Onkol 2006;182:501-10.
23. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
24. 31P magnetic resonance spectroscopy in human soft tissue tumours. Acta Oncol 1997;36:565-71.
25. Peng XH, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006;281:25903-14.
26. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7.
27. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.] Pathologe 1987;8:138-40.
28. Said HM, Staab A, Hagemann C, et al. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J Neurooncol 2007;81:27-38.
29. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
30. Sowter HM, Raval RR, Moore JW, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003;63:6130-4.
31. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-54.
32. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001;20:5779-88.
33. Swinson DE, Jones JL, Cox G, et al. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004;111:43-50.
34. Swinson DE, O'Byrne KJ. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 2006;7:250-6.
35. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
36. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
37. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.
38. Vaupel P, Mayer A, Hockel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.
39. Vordermark D, Brown JM Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-11.
40. Vordermark D, Kaffer A, Riedl S, et al. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005;61:1197-207.
41. Vordermark D, Kraft P, Katzer A, et al. Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). Cancer Lett 2005;230:122-33.
42. Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006;107:757-66.